Pulmonx Co. (NASDAQ:LUNG - Get Free Report) CFO Mehul Joshi sold 14,384 shares of the stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $7.12, for a total transaction of $102,414.08. Following the sale, the chief financial officer now directly owns 113,986 shares of the company's stock, valued at $811,580.32. The trade was a 11.21 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.
Pulmonx Stock Up 0.5 %
Shares of NASDAQ:LUNG traded up $0.04 during trading on Friday, hitting $7.48. 245,140 shares of the company were exchanged, compared to its average volume of 335,956. The stock has a market capitalization of $297.67 million, a P/E ratio of -5.19 and a beta of 0.50. The company has a debt-to-equity ratio of 0.40, a current ratio of 7.70 and a quick ratio of 6.77. Pulmonx Co. has a 12-month low of $5.46 and a 12-month high of $10.01. The firm's 50 day moving average price is $6.96 and its 200-day moving average price is $6.94.
Pulmonx (NASDAQ:LUNG - Get Free Report) last released its quarterly earnings results on Wednesday, February 19th. The company reported ($0.33) EPS for the quarter, beating the consensus estimate of ($0.45) by $0.12. Pulmonx had a negative net margin of 67.31% and a negative return on equity of 55.36%. The firm had revenue of $23.77 million during the quarter, compared to the consensus estimate of $22.29 million. On average, research analysts predict that Pulmonx Co. will post -1.55 earnings per share for the current fiscal year.
Analyst Ratings Changes
A number of equities research analysts recently commented on LUNG shares. Wells Fargo & Company decreased their target price on shares of Pulmonx from $10.00 to $8.00 and set an "equal weight" rating for the company in a research report on Wednesday, December 11th. Citigroup restated a "neutral" rating and set a $7.50 price target (down previously from $17.00) on shares of Pulmonx in a research report on Wednesday, December 11th. Two analysts have rated the stock with a hold rating and four have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $12.75.
Read Our Latest Stock Report on LUNG
Institutional Trading of Pulmonx
Several institutional investors and hedge funds have recently bought and sold shares of the business. FMR LLC raised its position in Pulmonx by 11.2% in the 3rd quarter. FMR LLC now owns 5,872,882 shares of the company's stock valued at $48,686,000 after purchasing an additional 591,859 shares during the last quarter. Deerfield Management Company L.P. Series C acquired a new position in Pulmonx in the 4th quarter valued at $10,421,000. BNP PARIBAS ASSET MANAGEMENT Holding S.A. increased its stake in Pulmonx by 5.2% in the 3rd quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 1,114,297 shares of the company's stock valued at $9,238,000 after buying an additional 55,279 shares during the period. JPMorgan Chase & Co. increased its stake in Pulmonx by 2.4% in the 3rd quarter. JPMorgan Chase & Co. now owns 1,055,522 shares of the company's stock valued at $8,750,000 after buying an additional 25,002 shares during the period. Finally, Geode Capital Management LLC increased its stake in Pulmonx by 1.1% in the 4th quarter. Geode Capital Management LLC now owns 902,240 shares of the company's stock valued at $6,128,000 after buying an additional 9,454 shares during the period. Hedge funds and other institutional investors own 91.04% of the company's stock.
About Pulmonx
(
Get Free Report)
Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation.
Featured Stories
Before you consider Pulmonx, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pulmonx wasn't on the list.
While Pulmonx currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
